| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA; and
* Department of Nutrition, Pennsylvania State University, University Park, Pennsylvania 16802, USA
2Correspondence: Department of Biochemistry, University of Wisconsin-Madison, 433 Babcock Dr., Madison, WI 53706-1544, USA. E-mail: deluca{at}biochem.wisc.edu
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONREFERENCES |
|---|
Key Words: autoimmune diseases • vitamin D as immunomodulator • inflammatory disease • vitamin D and immunity
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONREFERENCES |
|---|
In 1968, the idea appeared that vitamin D itself is biologically inactive and must be metabolically activated before it can function (1
, 2)
. This led to the isolation and chemical identification of the active forms of vitamin D in 1968–1971 (3)
. Continued pursuit of the metabolism of vitamin D resulted in the understanding that vitamin D must first be hydroxylated in the liver to form 25-hydroxyvitamin D3 (25-OH-D3), the major circulating form of the vitamin. This form of vitamin D was subsequently found to be metabolically inactive and must be further converted to a final active form, 1
,25-dihydroxyvitamin D3 (1,25-(OH)2D3) (3
, 4)
. This last step occurs predominantly if not exclusively in the proximal convoluted tubule cells of the kidney to produce the metabolically active form of vitamin D, 1,25-(OH)2D3. This major calcium mobilizing hormone then functions directly on the enterocyte of the small intestine to markedly increase the absorption of calcium and phosphorus from the lumen into the plasma compartment. It also plays a major role in the mobilization of calcium from bone when parathyroid hormone is present. Together with parathyroid hormone, it markedly improves the renal reabsorption of calcium in the distal tubule (3
, 4)
. These actions result in the elevation of plasma calcium and phosphorus levels to supersaturating conditions that are necessary to support mineralization of the skeleton on the one hand and prevent hypocalcemic tetany on the other (3
, 4)
. The production of the vitamin D hormone is regulated by the need for calcium and phosphorus (4
5
6)
. Slightly low levels of plasma calcium will stimulate the parathyroids to produce and secrete the parathyroid hormone. This hormone binds to osteoblasts of bone and the entire length of the nephron of the kidney (3
4
5)
. In the kidney, parathyroid hormone stimulates the 1-hydroxylase enzyme that produces the final vitamin D hormone. If calcium in plasma rises to very high levels, calcitonin is secreted from the c cells of the thyroid gland. This peptide hormone binds to the osteoblasts and osteoclasts to prevent the mobilization of calcium from bone; thus causing a reduction in plasma calcium levels. The exact details of this elegant endocrine system are reported elsewhere (1
2
3
4
5)
The attempt to understand how the active form of vitamin D carries out its functions led to the discovery of the vitamin D receptor (VDR) in 1974 and 1975 (6
, 7)
. Before this, however, synthesis of radiolabeled 1,25-(OH)2D3 of high specific activity allowed for frozen section autoradiography of physiological doses of this hormone. It became clear that this hormone localized almost entirely in the nucleus in a specific fashion in target tissues. This localization was also found in other tissues not previously considered targets (8
, 9)
. For example, keratinocytes of skin, islet cells of the pancreas, lymphocytes, and promyelocytes showed specific nuclear localization of 1,25-(OH)2D3 and the presence of the VDR. The discovery of the VDR in these tissues resulted in the idea that the vitamin D hormone had functions beyond calcium and phosphorus metabolism, which prompted investigations into the noncalcemic actions of the vitamin D hormone (10)
. Perhaps the most important was the discovery of the VDR in the parathyroid glands (9
, 11
, 12)
and the demonstration that the vitamin D hormone functions through its receptor to suppress the preproparathyroid gene (13)
and parathyroid cell proliferation (14)
. This, then, is the basis of the treatment of secondary hyperparathyroidism found in the dialysis patients and constitutes a major therapeutic application of 1,25-(OH)2D3 and its analogs.
Noting VDR in promyelocytes, Abe et al. and Tanaka et al. demonstrated that the vitamin D hormone can suppress proliferation of promyelocytes and cause their differentiation into the monocyte (15
, 16)
. Similar effects of the vitamin D hormone on several cancerous cell lines ensued (17)
. A role for the vitamin D hormone in cellular differentiation thus became known. These findings prompted a search to use vitamin D analogs to treat cancer and underscored the idea that the vitamin D hormone has functions beyond calcium, phosphorus, and bone. Table 1
provides a list of possible target cells of the vitamin D hormone including the classical sites of intestine, kidney, and bone.
|
The work of Manolagas and his group provided the first strong evidence that activated lymphocytes contain significant quantities of the VDR (18
19
20)
. Numerous in vitro studies followed in which the vitamin D hormone could be shown to increase proliferation or suppress proliferation, depending on the experiment and how it was conducted (21)
. It is undeniable that peripheral lymphocytes, macrophages, and thymus tissue contain the VDR. In fact, calf thymus proved to be an excellent source of the VDR to be used for competitive binding assays in the measurement of the vitamin D hormone (22)
. These findings then raised the question of what effect vitamin D might have on the immune system.
In our own laboratory we determined which cells of the lymphocyte population contain the largest amounts of the VDR (21)
. By purifying lymphocytes to homogeneity, we were able to demonstrate that the CD-8 lymphocytes have the highest concentrations of the VDR, whether or not they were activated. Most important, the presence of 1,25-(OH)2D3 increases the amount of measurable receptor, probably because it improves the longevity and stability of the receptor in vivo as well as in vitro (23)
.The CD4 lymphocytes and macrophages contain relatively small but significant amounts of the VDR. Figure 1
illustrates the VDR levels in cells of the immune system.
|
The next important advance in the role of vitamin D in the immune system came from studies of vitamin D-deficient mice (24)
. Making mice vitamin D deficient proved not to be a trivial matter, and two generations of mice reproducing under low vitamin D conditions were required. Having accomplished this, S. Yang in my group demonstrated that delayed hypersensitivity response to dinitrobenzene is impaired under conditions of vitamin D deficiency (24)
. This same response was also suppressed with supplemental 1,25-(OH)2D3 (25)
. It became evident, therefore, that T cell-mediated immunity is under modulatory control of 1,25-(OH)2D3. In its absence, T cell-mediated immune responses were blunted; with high doses of the vitamin D hormone, the same response could also be blunted. Similar immunosuppression was reported with interesting analogs of the vitamin D hormone including 22-oxa-1,25-(OH)2D3 (26)
and the 16-ene-23-yne-1,25-(OH)2D (27)
. These vitamin D compounds began to be known as immunosuppressants.
Based on the reported immunosuppressant activities of the vitamin D hormone, we decided to test the idea that certain autoimmune diseases involving hyperactive T cell-mediated immunity might be suitable for further study (28)
. We focused on the disease, experimental autoimmune encephalomyelitis (EAE) in mice. We selected B10.PL mice as the model because the sequence of neural degenerative symptoms that result in these mice after myelin basic protein injection is similar to human multiple sclerosis (MS). We succeeded in establishing EAE and showed there was an incidence of 100% in B10.PL mice fed a 0.87% calcium diet containing dietary vitamin D. However, the provision of 1,25-(OH)2D3 at 50–200 ng/day could prevent the appearance of the EAE lesions. If the vitamin D compound was given postimmunization, it prevented further development of the disease (28)
. By now we have carried out extensive experiments on this experimental model of autoimmune disease and have found that the vitamin D compounds (including some important potent analogs) are extremely effective in blocking the development of EAE.
In our attempt to reduce the hypercalcemic effects of 1,25-(OH)2D3, we provided this compound to animals maintained on a very low calcium diet (29)
. To our surprise, the low calcium diet produced a lower incidence of disease that was resistant to treatment with the vitamin D hormone (29)
(see Fig. 2
). On the other hand, when similar examinations were followed in the high calcium diet, the vitamin D compounds were effective (Fig. 3
). Thus, it became clear that calcium is required for the vitamin D suppression of the autoimmune disease, EAE. Our initial clinical trial with the analog 19-nor-1,25-(OH)2D2 (30)
revealed little effectiveness in preventing new MS lesions primarily because we failed to simultaneously provide a normal to high calcium intake. The results, therefore, imply that a high calcium diet is required for the vitamin D hormone to be effective in the treatment of EAE.
|
|
The success with EAE suggested that vitamin D compounds could be used to treat other autoimmune disorders. Rheumatoid arthritis proved to be another example of an autoimmune disorder that can be largely prevented by the administration of the 1-hydroxylated vitamin D compounds, including 1,25-(OH)2D3 (31)
. Two autoimmune models of rheumatoid arthritis were used. One is the disorder caused by Lyme’s disease or the organism Borrelia burgdorferi; the other is collagen-induced arthritis. An example of collagen-induced arthritis and its prevention by the administration of 1,25-(OH)2D3 is illustrated in Fig. 4
. Although little more was done in studying this disorder, high calcium intakes were not required for vitamin D compounds to prevent the lesions.
|
Another example not yet reported in the literature from our group is systemic lupus erythematosus (SLE). In 1992, Lemire et al. described an attenuation of this disorder by 1,25-(OH)2D3 injected three times a week to MRL mice (32)
. However, they were unable to attenuate the rising proteinuria characteristic of this disorder and reduced the dietary calcium level in the group of mice receiving 1,25-(OH)2D3. Therefore, it is unclear whether the low calcium diet, the 1,25-(OH)2D3, or both caused the minimal improvement reported. In our research group, MRL mice were placed on either a 0.87% calcium, 0.3% phosphorus diet or a 0.02% calcium, 0.3% phosphorus-purified diet. As shown in Fig. 5
, nearly 75% of the MRL mice developed proteinuria by 17 wk on the 0.87% calcium, 0.3% phosphorus diet; 50 ng/day of 1,25-(OH)2D3 incorporated into the diet prevented the proteinuria. As shown in Fig. 5
, the severity of the MRL symptoms was also markedly prevented by the administration of 1,25-(OH)2D3. In the 0.02% calcium diet, however, the animals receiving 1,25-(OH)2D3 developed SLE symptoms earlier and appeared to be more severely affected than animals on the 0.02% calcium diet alone (Fig. 6
). Again, the results illustrate that a high calcium background is required for the vitamin D hormone to prevent the development of this autoimmune disorder in the MRL mice. This, then, agrees with the results obtained with EAE.
|
|
The laboratory of Margherita Cantorna has investigated the possible treatment or prevention of inflammatory bowel disease (IBD) by vitamin D (33)
. Vitamin D deficiency accelerated the appearance of symptoms and increased the severity of IBD in interleukin 10 (IL-10) knockout (KO) mice. Vitamin D-deficient IL-10 knockout mice developed symptoms of IBD within 6–8 wk (Fig. 7
). This was essentially prevented by the administration of 1,25-(OH)2D3, again under conditions of high calcium intakes.
|
In our own laboratory, we have investigated the development of type I diabetes in the nonobese diabetic (NOD) mouse model (34)
. These experiments were performed with animals on a 0.87% calcium, 0.3% phosphorus diet. Vitamin D deficiency markedly accelerated the appearance and increased the incidence of type I diabetes in the NOD mice (Fig. 8
). Administration of ordinary vitamin D partially protected the mice from developing diabetes but the rate of incidence was still on the order of 30–40%. Addition to the diet of 1,25-(OH)2D3 at 50 ng/day for females and 200 ng/day for males prevented the appearance of the diabetic lesions. Mathieu et al. also studied the appearance of diabetes in NOD mice and have reported some partial benefit by the injection of 1,25-(OH)2D3 three times a week together with a low calcium diet (35)
. It is not clear whether the improvement was due to the vitamin D or due to the low calcium diet from these studies. Furthermore, the protection appeared minimal. Another major difference was that we incorporated 1,25-(OH)2D3 into the diet at all meals vs. three times a week. With a half-life of between 2 and 4 h in animals, it seems unlikely that i.p. dosing three times/wk is sufficient. In any case, the autoimmune disorder in the NOD mice can be prevented by the administration of 1,25-(OH)2D3 if animals are receiving a normal to high calcium diet.
|
Hypercalcemia continues to be a problem and so there is an ongoing search for a true in vivo noncalcemic analog that is still able to prevent the autoimmune disorders. So far, this has not been successful but we are only now beginning to try to prepare true noncalcemic analogs that are effective in vivo. It is possible that the calcemic action of 1,25-(OH)2D3 is also required for treatment of these autoimmune disorders.
Another important development has been the use of vitamin D compounds to suppress or prevent transplant rejection (36
, 37)
. The work of Lemire et al. with a low calcium diet and 1,25-(OH)2D3 three times a week showed some improvement in maintaining transplanted organs (38)
. We have used the ear/heart transplant model to look at the effects of vitamin D compounds on transplant rejection. The donor mice differed from the recipient mice by two major histocompatability complex differences (allografts). After transplantation, the heart tissue in this model begins to beat at 7 days. In the isografts, no rejection took place in any of the animals; within 27 days, allograft rejection was complete. Cyclosporin A at relatively low doses appeared not to protect whereas 1,25-(OH)2D3 at 50 ng/day in the diet (again, along with 0.87% calcium) protected the animal for as long as 100 days. Vitamin D compounds may be useful in preventing transplant rejection.
The sum of these findings in whole animals clearly illustrates that T cell-mediated immunity can be regulated by exogenous administration of 1-hydroxylated vitamin D compounds. The absence of vitamin D from the diet might also increase the incidence and severity of autoimmune diseases, pointing to important regulatory actions of the vitamin D hormone.
The action of 1,25-(OH)2D3 as an immunosuppressant appears to be specific since it does not appear to interfere with the ability of the animal to act defensively against opportunist infection (37)
. We have tested whether vitamin D treatment of mice makes them more susceptible to two infectious diseases. One was an infection caused by the fungal pathogen Candida albicans, a common infection found in transplant patients; the other was susceptibility to a viral herpes infection. In both cases, no interference by the vitamin D compounds was found in the disease course brought about by these organisms, whereas identical vitamin D doses were fully effective in preventing transplant rejection. It is also important to realize that vitamin D does not appear to act on the B lymphocyte, primarily because the B lymphocyte does not contain VDR in appreciable amounts (21)
.
There have been numerous studies of in vitro behavior of a variety of T cells and macrophages, all actors in the immune system. Although these have been contradictory and difficult to interpret, we are beginning to see some progress in understanding the mechanism whereby vitamin D acts as an immunosuppressant in vivo. We have measured the mRNAs encoding cytokines in the lymphocytes found in the lymph nodes of control mice and those treated with 1,25-(OH)2D3 (39)
. As illustrated in Fig. 9
and Fig. 10
, vitamin D administration markedly increases TGFß-1 and IL-4 transcripts whereas there is a reduction, if anything, in interferon 
and tumor necrosis factor gene expression. These results do not differentiate between the direct effects of vitamin D on cytokine gene expression and the indirect effects of vitamin D as regulators of other cells and genes that result in a net change in cytokine expression. With the availability of the IL-4 KO mice, we bred IL-4 KO mice onto the EAE susceptible B10.PL background. In the absence of IL-4, EAE was more severe. IL-4 KO mice with EAE are also resistant to treatment with 1,25-(OH)2D3 (40)
. Clearly, we are just beginning to probe the mechanisms whereby vitamin D hormone and its analogs can act as selective immunosuppressants. We do not understand the mechanism whereby the vitamin D hormone can act as an immunosuppressant especially of T cell-mediated inflammatory responses.
|
|
Despite reports to the contrary, there are no in vivo analogs that seem to act without hypercalcemia. Suppression of autoimmune disease requires not only the active form of vitamin D and its analogs, but also adequate or high calcium intakes. Further complicating the picture, little has been done to understand how vitamin D deficiency influences delayed type hypersensitivity. It is not clear whether the suppression of delayed type hypersensitivity response seen during vitamin D deficiency is due to the secondary effect of hypocalcemia or is a direct action of vitamin D on certain components of the immune system. This is a complicated and fertile area of investigation, from which may emerge important new therapies for autoimmune disease.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONREFERENCES |
|---|
,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 78,4990-4994,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). The presence of a cytosol receptor and induction of differentiation. Biochem. J 204,713-719[Medline]
,25-Dihydroxyvitamin D3 and 19-nor-1,25-dihydroxyvitamin D2 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo. Biochim. Biophys. Acta 1158,279-386[Medline]
,25-dihydroxyvitamin D3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice. Endocrinology 124,2645-2647This article has been cited by other articles:
|
|
 |
|
  Z. Ozfirat and T. A Chowdhury Vitamin D deficiency and type 2 diabetes Postgrad. Med. J., January 1, 2010; 86(1011): 18 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Zella, M. B. Meyer, R. D. Nerenz, and J. W. Pike The Enhanced Hypercalcemic Response to 20-Epi-1,25-Dihydroxyvitamin D3 Results from a Selective and Prolonged Induction of Intestinal Calcium-Regulating Genes Endocrinology, August 1, 2009; 150(8): 3448 - 3456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Szeto and P. K.-T. Li The use of vitamin D analogues in chronic kidney diseases: possible mechanisms beyond bone and mineral metabolism NDT Plus, June 1, 2009; 2(3): 205 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tang, R. Zhou, D. Luger, W. Zhu, P. B. Silver, R. S. Grajewski, S.-B. Su, C.-C. Chan, L. Adorini, and R. R. Caspi Calcitriol Suppresses Antiretinal Autoimmunity through Inhibitory Effects on the Th17 Effector Response J. Immunol., April 15, 2009; 182(8): 4624 - 4632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Zipitis Is Vitamin D Protective Against Development of Type 1 Diabetes Mellitus? ICAN: Infant, Child, & Adolescent Nutrition, April 1, 2009; 1(2): 108 - 112. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Tentori, J. M. Albert, E. W. Young, M. J. Blayney, B. M. Robinson, R. L. Pisoni, T. Akiba, R. N. Greenwood, N. Kimata, N. W. Levin, et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study Nephrol. Dial. Transplant., March 1, 2009; 24(3): 963 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bruce, J. P. Whitcomb, A. August, M. A. McDowell, and M. T. Cantorna Elevated non-specific immunity and normal Listeria clearance in young and old vitamin D receptor knockout mice Int. Immunol., February 1, 2009; 21(2): 113 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kragt, B. van Amerongen, J Killestein, C. Dijkstra, B. Uitdehaag, C. Polman, and P Lips Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women Multiple Sclerosis, January 1, 2009; 15(1): 9 - 15. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Bikle Nonclassic Actions of Vitamin D J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 26 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yu, D. Bruce, M. Froicu, V. Weaver, and M. T. Cantorna Failure of T cell homing, reduced CD4/CD8{alpha}{alpha} intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice PNAS, December 30, 2008; 105(52): 20834 - 20839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bouillon, G. Carmeliet, L. Verlinden, E. van Etten, A. Verstuyf, H. F. Luderer, L. Lieben, C. Mathieu, and M. Demay Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice Endocr. Rev., October 1, 2008; 29(6): 726 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mouyis, A. J. K. Ostor, A. J. Crisp, A. Ginawi, D. J. Halsall, N. Shenker, and K. E. S. Poole Hypovitaminosis D among rheumatology outpatients in clinical practice Rheumatology, September 1, 2008; 47(9): 1348 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shuvy, S. Abedat, R. Beeri, H. D. Danenberg, D. Planer, I. Z. Ben-Dov, K. Meir, J. Sosna, and C. Lotan Uraemic hyperparathyroidism causes a reversible inflammatory process of aortic valve calcification in rats Cardiovasc Res, August 1, 2008; 79(3): 492 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. McCann and B. N. Ames Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J, April 1, 2008; 22(4): 982 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cutolo and K. Otsa Review: Vitamin D, immunity and lupus Lupus, January 1, 2008; 17(1): 6 - 10. [Abstract] [PDF]
|
|
|
|
 |
|
 J B. Richards, A. M Valdes, J. P Gardner, D. Paximadas, M. Kimura, A. Nessa, X. Lu, G. L Surdulescu, R. Swaminathan, T. D Spector, et al. Higher serum vitamin D concentrations are associated with longer leukocyte telomere length in women Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1420 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ehrchen, L. Helming, G. Varga, B. Pasche, K. Loser, M. Gunzer, C. Sunderkotter, C. Sorg, J. Roth, and A. Lengeling Vitamin D receptor signaling contributes to susceptibility to infection with Leishmania major FASEB J, October 1, 2007; 21(12): 3208 - 3218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. W. Seely Calciotropic Hormones in Preeclampsia: A Renewal of Interest J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3402 - 3403. [Full Text] [PDF]
|
|
|
|
|
|
K. D Cashman Vitamin D in childhood and adolescence Postgrad. Med. J., April 1, 2007; 83(978): 230 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Penna, S. Amuchastegui, N. Giarratana, K. C. Daniel, M. Vulcano, S. Sozzani, and L. Adorini 1,25-Dihydroxyvitamin D3 Selectively Modulates Tolerogenic Properties in Myeloid but Not Plasmacytoid Dendritic Cells J. Immunol., January 1, 2007; 178(1): 145 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Penna, S. Amuchastegui, C. Cossetti, F. Aquilano, R. Mariani, F. Sanvito, C. Doglioni, and L. Adorini Treatment of Experimental Autoimmune Prostatitis in Nonobese Diabetic Mice by the Vitamin D Receptor Agonist Elocalcitol J. Immunol., December 15, 2006; 177(12): 8504 - 8511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Moore, S. Kato, W. Xie, D. J. Mangelsdorf, D. R. Schmidt, R. Xiao, and S. A. Kliewer International Union of Pharmacology. LXII. The NR1H and NR1I Receptors: Constitutive Androstane Receptor, Pregnene X Receptor, Farnesoid X Receptor {alpha}, Farnesoid X Receptor beta, Liver X Receptor {alpha}, Liver X Receptor beta, and Vitamin D Receptor Pharmacol. Rev., December 1, 2006; 58(4): 742 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. N. Evans, L. Nguyen, J. Chan, B. A. Innes, J. N. Bulmer, M. D. Kilby, and M. Hewison Effects of 25-Hydroxyvitamin D3 and 1,25-Dihydroxyvitamin D3 on Cytokine Production by Human Decidual Cells Biol Reprod, December 1, 2006; 75(6): 816 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Daniel, H. H. Radeke, N. A. Sartory, N. Zahn, U. Zuegel, A. Steinmeyer, and J. Stein The New Low Calcemic Vitamin D Analog 22-Ene-25-Oxa-Vitamin D Prominently Ameliorates T Helper Cell Type 1-Mediated Colitis in Mice J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 622 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Hanneman, H. M. Scull, K. D. Cooper, and E. D. Baron Effect of topical vitamin d analogue on in vivo contact sensitization. Arch Dermatol, October 1, 2006; 142(10): 1332 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Pike New Nonsteroidal Vitamin D Receptor Modulators: Are These Ligands the Real Deal? IBMS BoneKEy, June 1, 2006; 3(6): 14 - 18. [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Harris Vitamin D and African Americans J. Nutr., April 1, 2006; 136(4): 1126 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. H. Al-oanzi, S. P. Tuck, N. Raj, J. S. Harrop, G. D. Summers, D. B. Cook, R. M. Francis, and H. K. Datta Assessment of Vitamin D Status in Male Osteoporosis Clin. Chem., February 1, 2006; 52(2): 248 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Penna, A. Roncari, S. Amuchastegui, K. C. Daniel, E. Berti, M. Colonna, and L. Adorini Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3 Blood, November 15, 2005; 106(10): 3490 - 3497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Dong, W. Lutz, T. M. Schroeder, L. A. Bachman, J. J. Westendorf, R. Kumar, and M. D. Griffin Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter PNAS, November 1, 2005; 102(44): 16007 - 16012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Holick The Vitamin D Epidemic and its Health Consequences J. Nutr., November 1, 2005; 135(11): 2739S - 2748S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nagpal, S. Na, and R. Rathnachalam Noncalcemic Actions of Vitamin D Receptor Ligands Endocr. Rev., August 1, 2005; 26(5): 662 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C E Jennings, C J Owen, V Wilson, and S H S Pearce A haplotype of the CYP27B1 promoter is associated with autoimmune Addison's disease but not with Graves' disease in a UK population J. Mol. Endocrinol., June 1, 2005; 34(3): 859 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Chen, M. T. Cencioni, D. F. Angelini, G. Borsellino, L. Battistini, and C. F. Brosnan Transcriptional Profiling of {gamma}{delta} T Cells Identifies a Role for Vitamin D in the Immunoregulation of the V{gamma}9V{delta}2 Response to Phosphate-Containing Ligands J. Immunol., May 15, 2005; 174(10): 6144 - 6152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Townsend, C. M. Banwell, M. Guy, K. W. Colston, J. L. Mansi, P. M. Stewart, M. J. Campbell, and M. Hewison Autocrine Metabolism of Vitamin D in Normal and Malignant Breast Tissue Clin. Cancer Res., May 1, 2005; 11(9): 3579 - 3586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Gysemans, A. K. Cardozo, H. Callewaert, A. Giulietti, L. Hulshagen, R. Bouillon, D. L. Eizirik, and C. Mathieu 1,25-Dihydroxyvitamin D3 Modulates Expression of Chemokines and Cytokines in Pancreatic Islets: Implications for Prevention of Diabetes in Nonobese Diabetic Mice Endocrinology, April 1, 2005; 146(4): 1956 - 1964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M T Abreu, V Kantorovich, E A Vasiliauskas, U Gruntmanis, R Matuk, K Daigle, S Chen, D Zehnder, Y-C Lin, H Yang, et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density Gut, August 1, 2004; 53(8): 1129 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. N. Evans, J. N. Bulmer, M. D. Kilby, and M. Hewison Vitamin D and Placental-Decidual Function Reproductive Sciences, July 1, 2004; 11(5): 263 - 271. [Abstract] [PDF]
|
|
|
|
|
|
M. F Holick Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis Am. J. Clinical Nutrition, March 1, 2004; 79(3): 362 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Barnes and R. C. Bucknall Vitamin D deficiency in a patient with systemic lupus erythematosus Rheumatology, March 1, 2004; 43(3): 393 - 394. [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Munger, S. M. Zhang, E. O'Reilly, M. A. Hernan, M. J. Olek, W. C. Willett, and A. Ascherio Vitamin D intake and incidence of multiple sclerosis Neurology, January 13, 2004; 62(1): 60 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Fronczak, A. E. Baron, H. P. Chase, C. Ross, H. L. Brady, M. Hoffman, G. S. Eisenbarth, M. Rewers, and J. M. Norris In Utero Dietary Exposures and Risk of Islet Autoimmunity in Children Diabetes Care, December 1, 2003; 26(12): 3237 - 3242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.J. Boucher Maternal and postnatal vitamin D ingestion influences rat aortic structure, function and elastin content: [Cardiovasc. Res. 2002;55:369-374] Cardiovasc Res, January 1, 2003; 57(1): 284 - 285. [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Roig, E. Richer, F. Canonne-Hergaux, P. Gros, and M. F. M. Cellier Regulation of NRAMP1 gene expression by 1{alpha},25-dihydroxy-vitamin D3 in HL-60 phagocytes J. Leukoc. Biol., May 1, 2002; 71(5): 890 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Meehan and H. F. DeLuca CD8+ T cells are not necessary for 1alpha ,25-dihydroxyvitamin D3 to suppress experimental autoimmune encephalomyelitis in mice PNAS, April 16, 2002; 99(8): 5557 - 5560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Meehan and H. F. DeLuca CD8+ T cells are not necessary for 1alpha ,25-dihydroxyvitamin D3 to suppress experimental autoimmune encephalomyelitis in mice PNAS, April 16, 2002; 99(8): 5557 - 5560. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
30 days postimmunization. Treated animals showed no symptoms (see Cantorna et al., ref 30
